Therapeutic efficacy of Sulforaphane in autism spectrum disorders and its association with gut microbiota: animal model and human longitudinal studies
To investigate the therapeutic effect of Sulforaphane (SFN) treatment on childhood ASD and its potential relationship with GM, we constructed a younger age ASD animal model using MIA induced ASD-like rat model and evaluated the therapeutic effect of SFN and investigate the potential role of GM by three-chamber social test and 16S rRNA sequencing, respectively. Meanwhile, we also conducted a longitudinal study to investigate the therapeutic effects of SFN on childhood ASD by recruiting patients aged 4-7 years with ASD and to explore the potential relationship between the therapeutic effects of SFN and GM. In summary, this study aims to reveal the role of SFN in the treatment of ASD in children and its potential relationship with GM through both clinical and animal studies, and to provide new insights into the treatment and pathogenesis of ASD.